Related Experiment Video
Updated: Mar 20, 2026
Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
Published on: March 27, 2021
Rabbit models as tools for preclinical cardiac electrophysiological safety testing: Importance of repolarization
István Baczkó1, Norbert Jost2, László Virág1
1Department of Pharmacology & Pharmacotherapy, University of Szeged, Dóm tér 12., 6720 Szeged, Hungary.
Abstract:
It is essential to more reliably assess the pro-arrhythmic liability of compounds in development. Current guidelines for pre-clinical and clinical testing of drug candidates advocate the use of healthy animals/tissues and healthy individuals and focus on the test compound's ability to block the hERG current and prolong cardiac ventricular repolarization. Also, pre-clinical safety tests utilize several species commonly used in cardiac electrophysiological studies. In this review, important species differences in cardiac ventricular repolarizing ion currents are considered, followed by the discussion on electrical remodeling associated with chronic cardiovascular diseases that leads to altered ion channel and transporter expression and densities in pathological settings. We argue that the choice of species strongly influences experimental outcome and extrapolation of results to human clinical settings. We suggest that based on cardiac cellular electrophysiology, the rabbit is a useful species for pharmacological pro-arrhythmic investigations. In addition to healthy animals and tissues, the use of animal models (e.g. those with impaired repolarization reserve) is suggested that more closely resemble subsets of patients exhibiting increased vulnerability towards the development of ventricular arrhythmias and sudden cardiac death.
Insights
Assessing drug pro-arrhythmic liability requires considering species differences in cardiac ion currents. Using rabbits and disease models may improve prediction of human cardiac risks.
Area of Science:
- Pharmacology
- Cardiology
- Drug Development
Background:
- Current drug safety testing focuses on healthy subjects and hERG current blockade.
- Species differences in cardiac ion currents and electrical remodeling in disease are critical.
- Existing methods may not accurately predict pro-arrhythmic risks in diverse patient populations.
Purpose of the Study:
- To review species differences in cardiac electrophysiology relevant to drug-induced arrhythmias.
- To discuss the impact of cardiovascular diseases on cardiac ion channel function.
- To propose improved strategies for preclinical assessment of pro-arrhythmic liability.
Main Methods:
- Review of existing literature on species-specific cardiac electrophysiology.
- Analysis of electrical remodeling in chronic cardiovascular disease models.
- Comparison of ion channel function across species.
Main Results:
- Significant species-specific variations exist in cardiac ventricular repolarizing ion currents.
- Chronic cardiovascular diseases induce electrical remodeling, altering ion channel expression and function.
- The rabbit model demonstrates utility for pro-arrhythmic liability studies based on cellular electrophysiology.
Conclusions:
- Species choice significantly impacts the extrapolation of preclinical drug safety data to humans.
- Utilizing rabbit models and disease-specific animal models enhances the prediction of pro-arrhythmic risks.
- Integrating insights into electrical remodeling and species differences is crucial for reliable drug safety assessment.
